Combination therapy targeting Alzheimer's disease risk factors is associated with a significant delay in Alzheimer's disease–related cognitive decline
QuadRx slowed Alzheimer's disease (AD) cognitive decline by 47% in the National Alzheimer's Coordinating Center NACC and 60% in Alzheimer's Disease Neuroimaging Initiative ADNI participants.Combination therapy exhibited additive and synergistic slowing of cognitive decline.QuadRx was equally effective in females and males at 5 and 10 years.QuadRx mitigated the impact of the apolipoprotein E ε4 genotype.QuadRx was effective in AD participants reporting drug use for their AD risk factor.
Authors
- Roberta Dı́az Brinton (ORCID: https://orcid.org/0000-0001-8450-772X)
- Georgina Torrandell‐Haro (ORCID: https://orcid.org/0000-0003-2872-8282)
- Francesca Vitali (ORCID: https://orcid.org/0000-0003-2916-6402)
- Yuan Shang (ORCID: https://orcid.org/0000-0002-7093-4234)
Institutions
- University of Arizona (US)
- Arizona Science Center (US)
- Center for Innovation (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/trc2.70074
- Citations
- 1
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Alzheimer's Drug Discovery Foundation
- Alzheimer's Disease Neuroimaging Initiative
- National Institute on Aging